Project Grant R21AG098113
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $645,245 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded April 1, 2026, with a completion date of March 31, 2031. This five-year award supports research investigating the effect of DDX41 mutations on hematopoiesis during aging, specifically examining the role of these mutations in myelodysplastic syndromes (MDS), a group of bone marrow...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $511,987 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 27, 2025, with a completion date of May 31, 2029. This award funds a comparative research study investigating the molecular mechanisms of lamin A/C (LMNA)-related dilated cardiomyopathy, a severe form of adult-onset heart disease. The...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $441,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with a completion date of July 31, 2027. The award supports basic immunological research investigating the cell-specific roles of CD153 and CD30 in regulating immune responses, with particular focus on age-related immune...
- Federal Project Grant Award Summary The University of California, San Diego received a $437,375 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) for the period September 1, 2025 through August 31, 2027. The award funds biomedical research investigating NEK7 (NIMA-related kinase-7) as a potential suppressor of inflammation in aging hearts through regulation of RNA-binding proteins. The research addresses the critical connection between...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Boston Children's Hospital a Project Grant of $167,940 on August 15, 2025, under the Aging Research program (CFDA 93.866) to investigate the neuronal mechanisms underlying cognitive resilience to Alzheimer's disease (AD). The research project, which will be completed by May 31, 2030, aims to elucidate how MEF2 transcription factors (MEF2A and MEF2C) promote neuronal survival and cognitive resilience in individuals with...
- Federal Project Grant Award Summary The University of California, San Diego received a $439,750 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) for the period May 1, 2026 through April 30, 2028. This award funds research investigating the molecular mechanisms of nucleophagy—the autophagic degradation of nuclear envelope regions—and its relationship to chronological aging. The research will employ genetic screening, biochemical analysis, and...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded J. David Gladstone Institutes a Project Grant totaling $1,587,554 under the Aging Research program (CFDA 93.866) to conduct biomedical research investigating mitochondrial deoxyribonucleic acid (mtDNA) compaction and its relationship to somatic mutation accumulation across the human lifespan. The research project, initiated on June 17, 2025, and scheduled for completion by April 30, 2030, will deliver scientific...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded the University of Missouri System $429,394 under the Aging Research program (CFDA 93.866) for a Project Grant focused on cardiac fibrosis research in aging-associated heart failure. The award, effective December 15, 2025 through November 30, 2027, supports research targeting LARP6 (LA Ribonucleoprotein 6), an RNA binding protein implicated in pathologic cardiac fibrosis. The research deliverables include investigation of...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a Project Grant totaling $132,705.00 on June 15, 2025, to The Children's Hospital Corporation (Boston Children's Hospital) under the Aging Research program (CFDA 93.866). This award supports research addressing hematopoietic clonal dominance during aging—a condition in which driver mutations cause a limited number of hematopoietic stem and progenitor cell (HSPC) clones to disproportionately contribute to blood cell...
- Federal Project Grant Award Summary Mayo Clinic received a $1.34 million Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through May 31, 2029. This award supports research aimed at discovering aging-associated genetic modifiers and developing therapies for anthracycline-induced cardiotoxicity (AIC), a cumulative dose-dependent cardiac toxicity that limits the clinical use of...
Cincinnati Children's Hospital Medical Center received a $445,500 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded on May 15, 2026, with a completion date of April 30, 2028. This award funds a research project investigating proteomic identification of nuclear rupture-associated proteins in laminopathy hearts, with a focus on understanding mechanisms underlying LMNA-related dilated cardiomyopathy (LMNA-DCM). The research deliverables include systematic identification of proteins recruited to nuclear rupture sites using proximity labeling techniques (BioID) in cardiomyocyte-specific LMNA-knockout mice, validation of candidate protein localization and association with ruptured versus repaired nuclei, and functional characterization of selected proteins through in vivo depletion studies to assess their roles in cellular outcomes following nuclear rupture. The project addresses a critical gap in understanding age-associated nuclear envelope dysfunction by identifying and characterizing proteins that regulate divergent cellular responses to nuclear rupture—ranging from pathological consequences such as gene expression defects and DNA damage to endogenous repair mechanisms. The research utilizes three rupture-associated protein markers (BANF1, LEMD2, and catalytically inactive cGAS) as experimental baits to discover novel protein interactions at nuclear rupture sites. Findings from this investigation are intended to enable development of therapeutic strategies to prevent nuclear rupture or promote repair mechanisms in cardiac tissue affected by LMNA-DCM and potentially other age-associated conditions involving nuclear envelope integrity.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $445.5k | 5/11/26 |